NewSquare Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$399K Buy
1,836
+231
+14% +$51.2K 0.03% 167
2025
Q4
$367K Sell
1,605
-514
-24% -$117K 0.03% 161
2025
Q3
$491K Buy
2,119
+393
+23% +$80K 0.03% 156
2025
Q2
$320K Buy
1,726
+638
+59% +$119K 0.02% 161
2025
Q1
$228K Buy
1,088
+557
+105% +$108K 0.02% 171
2024
Q4
$94.4K Buy
531
+530
+53,000% +$97.4K 0.01% 175
2024
Q3
$189 Hold
1
﹤0.01% 300
2024
Q2
$164 Sell
1
-373
-100% -$61.8K ﹤0.01% 315
2024
Q1
$68.1K Sell
374
-22
-6% -$3.79K 0.01% 166
2023
Q4
$61.4K Sell
396
-45
-10% -$6.56K 0.01% 181
2023
Q3
$65.7K Sell
441
-66
-13% -$9.69K 0.01% 187
2023
Q2
$68.3K Sell
507
-340
-40% -$49.9K 0.01% 186
2023
Q1
$135K Buy
847
+316
+60% +$48.3K 0.02% 160
2022
Q4
$85.8K Sell
531
-307
-37% -$47.1K 0.01% 163
2022
Q3
$112K Buy
838
+1
+0.1% +$143 0.01% 156
2022
Q2
$128K Sell
837
-31,093
-97% -$4.75M 0.02% 162
2022
Q1
$5.18M Buy
31,930
+30,866
+2,901% +$4.48M 0.55% 42
2021
Q4
$144K Hold
1,064
0.02% 170
2021
Q3
$115K Sell
1,064
-4,865
-82% -$556K 0.01% 178
2021
Q2
$668K Buy
5,929
+219
+4% +$24.7K 0.08% 131
2021
Q1
$618K Buy
5,710
+5,380
+1,630% +$575K 0.08% 124
2020
Q4
$35K Hold
330
﹤0.01% 186
2020
Q3
$29K Sell
330
-27
-8% -$2.54K ﹤0.01% 185
2020
Q2
$35K Sell
357
-818
-70% -$72K 0.01% 178
2020
Q1
$90K Buy
1,175
+759
+182% +$64.6K 0.02% 153
2019
Q4
$37K Hold
416
0.01% 184
2019
Q3
$31K Hold
416
0.01% 157
2019
Q2
$30K Sell
416
-20,085
-98% -$1.58M 0.01% 199
2019
Q1
$1.65M Buy
20,501
+939
+5% +$76.8K 0.32% 61
2018
Q4
$1.8M Buy
19,562
+137
+0.7% +$12K 0.38% 39
2018
Q3
$1.84M Buy
19,425
+1,329
+7% +$126K 0.35% 48
2018
Q2
$1.61M Buy
18,096
+1,880
+12% +$184K 0.33% 54
2018
Q1
$1.53M Sell
16,216
-341
-2% -$37.5K 0.33% 45
2017
Q4
$1.6M Sell
16,557
-90
-0.5% -$8.48K 0.37% 41
2017
Q3
$1.48M Buy
16,647
+4
+0% +$304 0.35% 40
2017
Q2
$1.21M Buy
16,643
+777
+5% +$52.2K 0.29% 50
2017
Q1
$1.03M Buy
15,866
+2,340
+17% +$147K 0.25% 59
2016
Q4
$847K Buy
13,526
+344
+3% +$21K 0.21% 76
2016
Q3
$831K Buy
13,182
+736
+6% +$47.6K 0.19% 78
2016
Q2
$771K Buy
12,446
+1,596
+15% +$97.3K 0.18% 73
2016
Q1
$620K Buy
10,850
+5,725
+112% +$319K 0.18% 84
2015
Q4
$304K Buy
5,125
+667
+15% +$38.4K 0.09% 106
2015
Q3
$243K Buy
4,458
+96
+2% +$6.25K 0.07% 102
2015
Q2
$293K Buy
4,362
+95
+2% +$6.2K 0.09% 99
2015
Q1
$250K Buy
4,267
+222
+5% +$13.4K 0.08% 100
2014
Q4
$265K Buy
4,045
+133
+3% +$8.38K 0.09% 104
2014
Q3
$226K Buy
3,912
+349
+10% +$19.4K 0.08% 113
2014
Q2
$201K Buy
+3,563
New +$187K 0.07% 114
2014
Q1
Sell
-3,576
Closed -$189K 238
2013
Q4
$189K Buy
3,576
+286
+9% +$14.1K 0.09% 87
2013
Q3
$147K Sell
3,290
-98
-3% -$4.34K 0.07% 95
2013
Q2
$140K Buy
+3,388
New +$148K 0.07% 93

Other funds holding ABBV

NewSquare Capital's ABBV Position: Q1 2026 in Review

NewSquare Capital increased its AbbVie (ABBV) stake by 14% in Q1 2026, buying an estimated $51.2K and bringing the position to 1,836 shares worth $399K. The position accounts for 0.03% of the portfolio, ranked #167.

NewSquare Capital first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $5.18M in Q1 2022. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • NewSquare Capital held 1,836 shares of AbbVie worth $399K as of Q1 2026.
  • NewSquare Capital bought 231 AbbVie shares in Q1 2026, an estimated $51.2K.
  • AbbVie made up 0.03% of NewSquare Capital's portfolio in Q1 2026, its #167 holding.
  • NewSquare Capital first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • NewSquare Capital's AbbVie position peaked at $5.18M in Q1 2022.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on NewSquare Capital's 13F filing for Q1 2026, filed 8 May 2026.